GSK, Novartis pledge funds for diseases that mostly affect the poor
GSK and Novartis on Thursday reinforced commitments to address neglected tropical diseases, as world leaders… Read More
2 years ago
GSK
Unilever’s offer for GSK’s consumer health raises doubts
Unilever faces a dilemma after its 50 billion pound ($68 billion) offer for GlaxoSmithKline's consumer… Read More
3 years ago
US secures 600,000 more doses of COVID-19 therapy Sotrovimab
The United States has agreed to buy 600,000 more doses of GSK and Vir Biotechnology's… Read More
3 years ago
New data shows GSK-Vir drug works against all Omicron mutations
British drugmaker GSK said on Tuesday its antibody-based COVID-19 therapy with U.S. partner Vir Biotechnology… Read More
3 years ago
GSK, CureVac’s next-gen COVID-19 vaccine shows promise
GlaxoSmithKline and CureVac said a study on macaque monkeys showed their jointly-developed mRNA COVID-19 vaccine… Read More
3 years ago
GSK drug shows promise as treatment in kidney disease patients
GSK said on Friday its anaemia drug for patients with kidney disease succeeded in late-stage… Read More
3 years ago
Sanofi, GSK get Indian approval for trial of COVID-19 vaccine
Sanofi and GlaxoSmithKline have received an approval from Indian authorities for a late-stage clinical trial… Read More
3 years ago
Sanofi, GSK launch final phase of Covid vaccine trials
The companies reported positive results from interim human trials earlier this month after a disappointing… Read More
4 years ago
GSK buys 10% of CureVac in vaccine tech deal
GSK and CureVac, backed by Microsoft billionaire Bill Gates, will work on developing up to… Read More
4 years ago
Britain nears US$625 million Sanofi/GSK COVID-19 vaccine deal: report
Britain is close to a 500 million pound ($624 million) supply deal with Sanofi and… Read More
4 years ago
World’s largest vaccine maker reveals COVID-19 vaccine plans
There is a notable name missing from the frontrunners in the race to test experimental… Read More
4 years ago
GSK to produce 1 billion doses of vaccine efficacy boosters
The world’s largest vaccine maker said it was in talks with governments to back a… Read More
5 years ago
GSK ends development of Ebola vaccine
While Ebola is a deadly and contagious disease, it is also still relatively rare, making… Read More
5 years ago
HIV drug wins European panel thumbs-up
GlaxoSmithKline’s two-drug treatment for HIV infections won marketing approval from a European Medicines Agency (EMA) Read More
6 years ago
GSK, Pfizer to merge consumer healthcare units
LONDON: Pharmaceutical giants GlaxoSmithKline and Pfizer on Wednesday announced a merger of their consumer healthcare… Read More
6 years ago
GSK ‘real world’ drug test has second success in asthma
LONDON: GlaxoSmithKline notched up a second win for its pioneering "real world" approach to testing… Read More
8 years ago
Gilead challenges GSK with strong HIV drug data
SEATTLE: Gilead Sciences has thrown down a challenge to GlaxoSmithKline with good clinical trial results… Read More
8 years ago
GSK cuts vaccine price for refugees, bowing to pressure
LONDON: GlaxoSmithKline is cutting the price charged for its pneumococcal vaccine when given to refugees,… Read More
8 years ago
‘Work on Ebola vaccine moving fast’
LONDON: Britain's biggest drugmaker GlaxoSmithKline said on Saturday work to develop a vaccine to combat… Read More
10 years ago
Clinical trial to start soon on Ebola vaccine
LONDON: A clinical trial of an experimental vaccine against the deadly Ebola virus is set… Read More
10 years ago